Smith & Nephew announce European launch of handheld imaging technology

Smith & Nephew would like to announce its European launch of MolecuLight i:X, a handheld imaging technology heralding a new era of evidence-based decision making in wound care.

With MolecuLight i:X wound assessment, surgeons and healthcare professionals can take an image of a wound which identifies the presence or absence of harmful fluorescent bacteria.

“One of the benefits of the MolecuLight i:X is that it will tell you instantly if there is a heavy burden of bacteria rather than having to wait several days for laboratory results, which delays treatment,” says Steven Jeffery Consultant Plastic Surgeon. “MolecuLight, in real-time allows me to diagnose and prescribe treatment quickly and effectively.”

 MolecuLight has been shown to:

• Reduce the average closure time of chronic wounds from 200 to 22 days - 9x improvement over standard care!
• More effective sampling - visualises the location and distribution of bacterial load across the wound bed and periphery, resulting in 54% more accurate swabbing
• Less unnecessary drug use – guides therapy and helps avoid over prescribing of antibiotics.